Skip to main content
Premium Trial:

Request an Annual Quote

Genetics of Afternoon Snoozes

How often someone takes a late-afternoon snooze could be partly genetic, a new study has found.

A Harvard Medical School-led team of researchers conducted a genome-wide association study of daytime napping using the UK Biobank and 23andMe datasets. The participants were asked if they never, sometimes, or often take naps during the day. As they report in Nature Communications, the researchers uncovered 61 loci linked to napping, including ones in regions tied to sleep disorders, arousal, and increased body-mass index. Some of these regions are already sleep disorder targets, they note.

The researchers add that clustering of these loci pointed to three scenarios that could underlie the need for a nap: a general requirement for more sleep, the result of poor or disrupted sleep, and, if combined with getting up early, a need to "catch up" on sleep.

"This tells us that daytime napping is biologically driven and not just an environmental or behavioral choice," co-first author Hassan Saeed Dashti from the Massachusetts General Hospital's Center for Genomic Medicine says in a statement.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.